|
covid-19 |
25 |
|
disease burden |
16 |
|
sars-cov-2 |
14 |
|
public health |
13 |
|
influenza virus |
12 |
|
reproduction number |
12 |
|
death |
11 |
|
human influenza |
11 |
|
vaccination |
11 |
|
disparities |
10 |
|
influenza |
10 |
|
intervention |
10 |
|
socioeconomic |
10 |
|
surveillance |
10 |
|
work from home |
10 |
|
hospitalization |
9 |
|
mass testing |
9 |
|
severity |
9 |
|
transmission dynamics |
9 |
|
immunity |
8 |
|
impact |
8 |
|
incidence rates |
8 |
|
transmission |
8 |
|
2009 h1n1 influenza |
7 |
|
adolescent |
7 |
|
antibody titer |
7 |
|
child |
7 |
|
incubation period |
7 |
|
influenza vaccine |
7 |
|
case clusters |
6 |
|
control |
6 |
|
epidemiological monitoring |
6 |
|
epidemiology |
6 |
|
generation time |
6 |
|
h7n9 subtype |
6 |
|
high-rise buildings |
6 |
|
humidity |
6 |
|
infectious disease outbreak |
6 |
|
influenza a |
6 |
|
influenza a virus |
6 |
|
interventions |
6 |
|
line list |
6 |
|
omicron variants |
6 |
|
pandemic preparedness |
6 |
|
pandemic responses |
6 |
|
prediction |
6 |
|
seasonality |
6 |
|
seriousness |
6 |
|
transmissibility |
6 |
|
viral loads |
6 |
|
controlled study |
5 |
|
coronavirus disease 2019 |
5 |
|
disease control |
5 |
|
disease severity |
5 |
|
disease transmission |
5 |
|
medical sciences |
5 |
|
cause of death |
4 |
|
epidemiologic methods |
4 |
|
excess mortality |
4 |
|
in-hospital mortality |
4 |
|
influenza‐like illness |
4 |
|
life expectancy |
4 |
|
life table |
4 |
|
mortality |
4 |
|
out-of-hospital mortality |
4 |
|
parametric bootstrap |
4 |
|
systematic review |
4 |
|
systematic reviews |
4 |
|
uncertainty |
4 |
|
age factors |
3 |
|
aircraft |
3 |
|
antimicrobial resistance |
3 |
|
asia-pacific |
3 |
|
coronavirus |
3 |
|
ebola virus |
3 |
|
hospitalisation |
3 |
|
influenza, human - epidemiology - prevention and control |
3 |
|
key words influenza |
3 |
|
methicillin resistance |
3 |
|
mrsa |
3 |
|
pandemics |
3 |
|
staphylococcus aureus |
3 |
|
travel |
3 |
|
2019 novel coronavirus disease |
2 |
|
breathing disorder |
2 |
|
care homes |
2 |
|
china |
2 |
|
classification |
2 |
|
communicable disease |
2 |
|
coughing |
2 |
|
disease surveillance |
2 |
|
education |
2 |
|
environmental protection |
2 |
|
epidemiological parameters |
2 |
|
hand washing |
2 |
|
households |
2 |
|
human |
2 |
|
infection control |
2 |
|
influenza - mathematical models |
2 |
|
influenza - mathematical models. |
2 |
|
influenza a (h1n1) |
2 |
|
influenza viruses |
2 |
|
lockdown |
2 |
|
mathematical modeling |
2 |
|
non-pharmaceutical interventions |
2 |
|
nonhealthcare settings |
2 |
|
nonhuman |
2 |
|
nonpharmaceutical measures |
2 |
|
pandemic |
2 |
|
public health surveillance - mathematical models |
2 |
|
public health surveillance - mathematical models. |
2 |
|
schools |
2 |
|
social distancing |
2 |
|
angioma |
1 |
|
autopsy |
1 |
|
children |
1 |
|
cohort study |
1 |
|
hiv |
1 |
|
infantile hemangioma |
1 |
|
lopinavir/ritonavir |
1 |
|
port wine stain |
1 |
|
vascular lesions |
1 |
|
virologic failure |
1 |